Tevogen Bio Holdings Inc.

TVGN

US88165K1016

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 20:23:47 28/06/2024 BST			5-day change	1st Jan Change
0.709 ^USD	-2.88%		-11.36%	-93.63%

06-25	Tevogen Bio Holdings Inc. Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances	CI
06-24	Tevogen Bio Holdings Inc.(NasdaqGM:TVGN) added to S&P TMI Index	CI

Tevogen Bio Holdings Inc.(NasdaqGM:TVGN) added to S&P TMI Index

June 23, 2024

Latest news about Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances	06-25	CI
Tevogen Bio Holdings Inc.(NasdaqGM:TVGN) added to S&P TMI Index	06-23	CI
Tevogen Bio Confirms Ongoing Efficacy of Tvgn 489, Its Investigational Allogeneic Off-The-Shelf Immunotherapy, Against Dominant Flirt Strains of Sars-Cov-2	06-06	CI
Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday	05-13	MT
Top Premarket Gainers	05-13	MT
Tevogen Bio Holdings Inc. announced that it expects to receive $50 million in funding	05-09	CI
Sector Update: Health Care Stocks Higher in Afternoon Trading	04-26	MT
Tevogen Bio Shares Jump Following Report on $94.9 Million Liability Elimination	04-26	MT
Top Premarket Gainers	04-26	MT
Top Premarket Gainers	04-04	MT
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development	04-03	CI
Tevogen Bio Holdings Inc. amended terms of the transaction	03-26	CI
Tevogen Bio Holdings Announces TVGN 489, its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant	03-20	CI
Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment	02-21	CI
Tevogen Bio Holdings Inc.(NasdaqGM:TVGN) added to NASDAQ Composite Index	02-14	CI
Tevogen Bio Holdings Inc. announced that it expects to receive $2 million in funding	02-13	CI
Tevogen Bio Holdings Inc. announced that it expects to receive $8 million in funding	02-13	CI

Chart Tevogen Bio Holdings Inc.

Duration

Period

More charts

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.73 USD

Average target price

4.2 USD

Spread / Average Target

+475.34%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TEVOGEN BIO HOLDINGS INC.	-93.63%	121M
LONZA GROUP AG	+38.65%	39.1B
IQVIA HOLDINGS INC.	-9.18%	38.76B
ALNYLAM PHARMACEUTICALS, INC.	+27.06%	31.24B
ICON PUBLIC LIMITED COMPANY	+10.97%	25.9B
CELLTRION, INC.	-13.50%	25.8B
UNITED THERAPEUTICS CORPORATION	+43.72%	14.06B
MEDPACE HOLDINGS, INC.	+33.76%	13.12B
BIO-TECHNE CORPORATION	-8.19%	11.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-13.11%	10.68B

Other Biotechnology & Medical Research